Never Gonna Give You Up – Current Developments in Covalent Protein Kinase Inhibitors
Covalent inhibitors have recently seen a revival in medicinal chemistry. Inhibitors addressing non-catalytic cysteine residues with weakly reactive electrophiles have been very successfully employed to target protein kinases, one of the major druggable protein families. Here we provide an overview...
Main Authors: | Laura Hillebrand, Matthias Gehringer |
---|---|
Format: | Article |
Language: | deu |
Published: |
Swiss Chemical Society
2022-05-01
|
Series: | CHIMIA |
Subjects: | |
Online Access: | https://chimia.ch/chimia/article/view/6037 |
Similar Items
-
Covalent Warheads Targeting Cysteine Residue: The Promising Approach in Drug Development
by: Fangjiao Huang, et al.
Published: (2022-11-01) -
Systematic Analysis of Covalent and Allosteric Protein Kinase Inhibitors
by: Elena Xerxa, et al.
Published: (2023-08-01) -
Discovery of a Novel Class of Covalent Dual Inhibitors Targeting the Protein Kinases BMX and BTK
by: Michael Forster, et al.
Published: (2020-12-01) -
Covalency-enabled Drug Discovery is Redefining Druggability
by: Jeffrey M. McKenna, et al.
Published: (2023-08-01) -
Extended Applications of Small-Molecule Covalent Inhibitors toward Novel Therapeutic Targets
by: Jesang Lee, et al.
Published: (2022-11-01)